Regulatory Brief

 Making a new embutramide-based euthanasia solution a controlled substance


Formal title: Docket Number [DEA-269P]; Schedules of Controlled Substances: Placement of Embutramide Into Schedule III


Summary:

The DEA is proposing to schedule the substance embutramide and products containing embutramide as Schedule III controlled substances.

The AVMA supports placement of the substance embutramide into Schedule III of the Controlled Substances Act to reduce the potential for drug diversion. However, the AVMA does not support scheduling of the FDA approved, prescription drug Tributame™ Euthanasia Solution because the characteristics of the final formulation vitiate the potential for abuse and the benefits of an unscheduled humane euthanasia solution are exceedingly valuable.

Background Documents:

 

View Federal Register document (PDF)

View AVMA's response to DEA (PDF)

Conclusion:

The DEA concluded that the substance embutramide and any drug product containing embutramide are subject to schedule III requirements.

View DEA conclusion (PDF)